Cereno Scientific joins PVRI as a Roundtable member

Cereno Scientific, a pioneering biotech developing innovative treatments for rare and common cardiovascular diseases, has joined PVRI as a Roundtable member. 

Lead drug candidate, CS1, an HDAC inhibitor acting as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, is being evaluated in a Phase II study in pulmonary arterial hypertension (PAH). Two initiatives, including a patient case, have shown positive findings suggesting potential clinical benefit of CS1 in PAH patients. In 12 weeks of treatment with CS1, the patient showed a 30% reduction in pulmonary pressure and a 20% increase in cardiac output, with an overall functional status changed from NYHA/WHO functional class II to I at the end of the treatment period. Since January 2024, the FDA´s Expanded Access Program will give patients with PAH access to CS1 where no comparable alternative therapy options are available. Final Phase II topline results are expected in Q3 2024. 

Cereno’s portfolio also comprises CS014, an HDAC inhibitor with epigenetic effects, being developed for thrombosis prevention, Phase I planned in Q2 2024, and CS585 in preclinical development, yet to be assigned a specific indication, with preclinical data indicating that it could potentially be used in indications like PH and thrombosis prevention without increased risk of bleeding. 

“We are delighted to welcome Cereno Scientific to our Roundtable. They’ll bring energy and expertise to our IDDI Workstreams and help us tackle some of the key challenges in drug development. The collaboration follows Cereno’s participation at our PVRI 2024 Congress in London.”, Karen Osborn, PVRI CEO 

“We are very happy to have joined the PVRI Roundtable, and to formalize our relationship with PVRI for a closer collaboration to drive innovation of new treatments, to the benefit of patients and society, in these debilitating diseases”, said Sten R Sörensen, CEO, Cereno Scientific. 

The company is headquartered in Gothenburg, Sweden, and has a US subsidiary based in Boston, Massachusetts. Cereno is listed on the Nasdaq First North (CRNO B). Visit www.cerenoscientific.com to learn more.